Morning Briefing
Summaries of health policy coverage from major news organizations
Crucell, GSK Sign Agreement To Develop 'Second Generation Malaria Vaccine'
Crucell, the Dutch biotechnology company, "said on Tuesday it had agreed with Britain's GlaxoSmithKline [GSK] to jointly develop a malaria vaccine candidate, without disclosing financial details," Reuters reports (Gray-Block, 4/6).
This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
